RESUMEN
Chondrosarcoma is a heterogeneous collection of malignant bone tumors and is the second most common primary malignancy of bone after osteosarcoma. Recent work has identified frequent, recurrent mutations in IDH1 or IDH2 in nearly half of central chondrosarcomas. However, there has been little systematic genomic analysis of this tumor type, and, thus, the contribution of other genes is unclear. Here we report comprehensive genomic analyses of 49 individuals with chondrosarcoma (cases). We identified hypermutability of the major cartilage collagen gene COL2A1, with insertions, deletions and rearrangements identified in 37% of cases. The patterns of mutation were consistent with selection for variants likely to impair normal collagen biosynthesis. In addition, we identified mutations in IDH1 or IDH2 (59%), TP53 (20%), the RB1 pathway (33%) and Hedgehog signaling (18%).
Asunto(s)
Neoplasias Óseas/genética , Condrosarcoma/genética , Colágeno Tipo II/genética , Mutación , Neoplasias Óseas/metabolismo , Neoplasias Óseas/patología , Condrosarcoma/metabolismo , Condrosarcoma/patología , Colágeno Tipo II/metabolismo , Biología Computacional , Variaciones en el Número de Copia de ADN , Bases de Datos Genéticas , Proteínas Hedgehog/genética , Proteínas Hedgehog/metabolismo , Humanos , Clasificación del Tumor , Polimorfismo de Nucleótido Simple , Proteína de Retinoblastoma/genética , Proteína de Retinoblastoma/metabolismo , Transducción de SeñalRESUMEN
The cancer genome is moulded by the dual processes of somatic mutation and selection. Homozygous deletions in cancer genomes occur over recessive cancer genes, where they can confer selective growth advantage, and over fragile sites, where they are thought to reflect an increased local rate of DNA breakage. However, most homozygous deletions in cancer genomes are unexplained. Here we identified 2,428 somatic homozygous deletions in 746 cancer cell lines. These overlie 11% of protein-coding genes that, therefore, are not mandatory for survival of human cells. We derived structural signatures that distinguish between homozygous deletions over recessive cancer genes and fragile sites. Application to clusters of unexplained homozygous deletions suggests that many are in regions of inherent fragility, whereas a small subset overlies recessive cancer genes. The results illustrate how structural signatures can be used to distinguish between the influences of mutation and selection in cancer genomes. The extensive copy number, genotyping, sequence and expression data available for this large series of publicly available cancer cell lines renders them informative reagents for future studies of cancer biology and drug discovery.
Asunto(s)
Sitios Frágiles del Cromosoma/genética , Eliminación de Gen , Genes Relacionados con las Neoplasias/genética , Genes Recesivos/genética , Genoma Humano/genética , Homocigoto , Neoplasias/genética , Selección Genética/genética , Línea Celular Tumoral , Cromosomas Humanos/genética , Variaciones en el Número de Copia de ADN/genética , Análisis Mutacional de ADN , Dosificación de Gen/genética , Humanos , Modelos Genéticos , Análisis de Secuencia por Matrices de Oligonucleótidos , Mapeo Físico de Cromosoma , Reproducibilidad de los ResultadosRESUMEN
We have identified one frameshift mutation, one splice-site mutation, and two missense mutations in highly conserved residues in ZDHHC9 at Xq26.1 in 4 of 250 families with X-linked mental retardation (XLMR). In three of the families, the mental retardation phenotype is associated with a Marfanoid habitus, although none of the affected individuals meets the Ghent criteria for Marfan syndrome. ZDHHC9 is a palmitoyltransferase that catalyzes the posttranslational modification of NRAS and HRAS. The degree of palmitoylation determines the temporal and spatial location of these proteins in the plasma membrane and Golgi complex. The finding of mutations in ZDHHC9 suggests that alterations in the concentrations and cellular distribution of target proteins are sufficient to cause disease. This is the first XLMR gene to be reported that encodes a posttranslational modification enzyme, palmitoyltransferase. Furthermore, now that the first palmitoyltransferase that causes mental retardation has been identified, defects in other palmitoylation transferases become good candidates for causing other mental retardation syndromes.
Asunto(s)
Aciltransferasas/genética , Síndrome de Marfan/complicaciones , Síndrome de Marfan/genética , Discapacidad Intelectual Ligada al Cromosoma X/complicaciones , Discapacidad Intelectual Ligada al Cromosoma X/genética , Mutación , Aciltransferasas/metabolismo , Secuencia de Aminoácidos , Secuencia de Bases , ADN/genética , Femenino , Humanos , Masculino , Síndrome de Marfan/enzimología , Discapacidad Intelectual Ligada al Cromosoma X/enzimología , Datos de Secuencia Molecular , Linaje , Fenotipo , Homología de Secuencia de Aminoácido , Proteínas ras/metabolismoRESUMEN
In a systematic sequencing screen of the coding exons of the X chromosome in 250 families with X-linked mental retardation (XLMR), we identified two nonsense mutations and one consensus splice-site mutation in the AP1S2 gene on Xp22 in three families. Affected individuals in these families showed mild-to-profound mental retardation. Other features included hypotonia early in life and delay in walking. AP1S2 encodes an adaptin protein that constitutes part of the adaptor protein complex found at the cytoplasmic face of coated vesicles located at the Golgi complex. The complex mediates the recruitment of clathrin to the vesicle membrane. Aberrant endocytic processing through disruption of adaptor protein complexes is likely to result from the AP1S2 mutations identified in the three XLMR-affected families, and such defects may plausibly cause abnormal synaptic development and function. AP1S2 is the first reported XLMR gene that encodes a protein directly involved in the assembly of endocytic vesicles.
Asunto(s)
Subunidades sigma de Complejo de Proteína Adaptadora/genética , Discapacidad Intelectual Ligada al Cromosoma X/genética , Mutación , Subunidades sigma de Complejo de Proteína Adaptadora/metabolismo , Adulto , Niño , Endosomas/metabolismo , Femenino , Humanos , Masculino , Discapacidad Intelectual Ligada al Cromosoma X/etiología , Discapacidad Intelectual Ligada al Cromosoma X/psicología , LinajeRESUMEN
Malignant gliomas have a very poor prognosis. The current standard of care for these cancers consists of extended adjuvant treatment with the alkylating agent temozolomide after surgical resection and radiotherapy. Although a statistically significant increase in survival has been reported with this regimen, nearly all gliomas recur and become insensitive to further treatment with this class of agents. We sequenced 500 kb of genomic DNA corresponding to the kinase domains of 518 protein kinases in each of nine gliomas. Large numbers of somatic mutations were observed in two gliomas recurrent after alkylating agent treatment. The pattern of mutations in these cases showed strong similarity to that induced by alkylating agents in experimental systems. Further investigation revealed inactivating somatic mutations of the mismatch repair gene MSH6 in each case. We propose that inactivating somatic mutations of MSH6 confer resistance to alkylating agents in gliomas in vivo and concurrently unleash accelerated mutagenesis in resistant clones as a consequence of continued exposure to alkylating agents in the presence of defective mismatch repair. The evidence therefore suggests that when MSH6 is inactivated in gliomas, alkylating agents convert from induction of tumor cell death to promotion of neoplastic progression. These observations highlight the potential of large scale sequencing for revealing and elucidating mutagenic processes operative in individual human cancers.
Asunto(s)
Antineoplásicos Alquilantes/uso terapéutico , Neoplasias Encefálicas/genética , Proteínas de Unión al ADN/genética , Dacarbazina/análogos & derivados , Glioma/genética , Mutación , Recurrencia Local de Neoplasia/genética , Anciano , Neoplasias Encefálicas/tratamiento farmacológico , Neoplasias Encefálicas/enzimología , Dacarbazina/uso terapéutico , Femenino , Glioma/tratamiento farmacológico , Glioma/enzimología , Humanos , Masculino , Persona de Mediana Edad , Recurrencia Local de Neoplasia/enzimología , Proteínas Quinasas/genética , TemozolomidaRESUMEN
The protein kinase gene family is the most frequently mutated in human cancer. Previous work has documented activating mutations in the KIT receptor tyrosine kinase in testicular germ-cell tumors (TGCT). To investigate further the potential role of mutated protein kinases in the development of TGCT and to characterize the prevalence and patterns of point mutations in these tumors, we have sequenced the coding exons and splice junctions of the annotated protein kinase family of 518 genes in a series of seven seminomas and six nonseminomas. Our results show a remarkably low mutation frequency, with only a single somatic point mutation, a K277E mutation in the STK10 gene, being identified in a total of more than 15 megabases of sequence analyzed. Sequencing of STK10 in an additional 40 TGCTs revealed no further mutations. Comparative genomic hybridization and LOH analysis using SNP arrays demonstrated that the 13 TGCTs mutationally screened through the 518 protein kinase genes were uniformly aneuploid with consistent chromosomal gains on 12p, 8q, 7, and X and losses on 13q, 18q, 11q, and 4q. Our results do not provide evidence for a mutated protein kinase implicated in the development of TGCT other than KIT. Moreover, they demonstrate that the general prevalence of point mutations in TGCT is low, in contrast to the high frequency of copy number changes.
Asunto(s)
Neoplasias de Células Germinales y Embrionarias/genética , Proteínas Quinasas/genética , Proteínas Serina-Treonina Quinasas/genética , Seminoma/genética , Neoplasias Testiculares/genética , Adolescente , Adulto , Aberraciones Cromosómicas , Exones , Dosificación de Gen , Humanos , Masculino , Persona de Mediana Edad , Mutación PuntualRESUMEN
Protein kinases are frequently mutated in human cancer and inhibitors of mutant protein kinases have proven to be effective anticancer drugs. We screened the coding sequences of 518 protein kinases (approximately 1.3 Mb of DNA per sample) for somatic mutations in 26 primary lung neoplasms and seven lung cancer cell lines. One hundred eighty-eight somatic mutations were detected in 141 genes. Of these, 35 were synonymous (silent) changes. This result indicates that most of the 188 mutations were "passenger" mutations that are not causally implicated in oncogenesis. However, an excess of approximately 40 nonsynonymous substitutions compared with that expected by chance (P = 0.07) suggests that some nonsynonymous mutations have been selected and are contributing to oncogenesis. There was considerable variation between individual lung cancers in the number of mutations observed and no mutations were found in lung carcinoids. The mutational spectra of most lung cancers were characterized by a high proportion of C:G > A:T transversions, compatible with the mutagenic effects of tobacco carcinogens. However, one neuroendocrine cancer cell line had a distinctive mutational spectrum reminiscent of UV-induced DNA damage. The results suggest that several mutated protein kinases may be contributing to lung cancer development, but that mutations in each one are infrequent.
Asunto(s)
Neoplasias Pulmonares/enzimología , Neoplasias Pulmonares/genética , Mutación , Proteínas Quinasas/genética , Adenocarcinoma/enzimología , Adenocarcinoma/genética , Tumor Carcinoide/enzimología , Tumor Carcinoide/genética , Carcinoma de Células Grandes/enzimología , Carcinoma de Células Grandes/genética , Carcinoma de Células Escamosas/enzimología , Carcinoma de Células Escamosas/genética , Línea Celular Tumoral , Análisis Mutacional de ADN , HumanosRESUMEN
We examined the coding sequence of 518 protein kinases, approximately 1.3 Mb of DNA per sample, in 25 breast cancers. In many tumors, we detected no somatic mutations. But a few had numerous somatic mutations with distinctive patterns indicative of either a mutator phenotype or a past exposure.